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ABSTRACT
Safety and immunogenicity of 2 investigational formulations of diphtheria, tetanus and Haemophilus
inﬂuenzae type b antigens of the combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated
poliomyelitis-Hib vaccine (DTPa-HBV-IPV/Hib) were evaluated in a Primary (NCT01248884) and a Booster
vaccination (NCT01453998) study.
In the Primary study, 721 healthy infants (randomized 1:1:1) received 3 doses of DTPa-HBV-IPV/Hib
formulation A (DATAPa-HBV-IPV/Hib), or B (DBTBPa-HBV-IPV/Hib) or the licensed DTPa-HBV-IPV/Hib vaccine
(Infanrix hexa, GSK; control group) at 2, 3, 4 months of age. Infants were planned to receive a booster dose
at 12–15 months of age with the same formulation received in the Primary study; however, following high
incidence of fever associated with the investigational formulations in the Primary study, the Booster study
protocol was amended and all infants yet to receive a booster dose (N D 385) received the licensed vaccine.
In the Primary study, non-inferiority of 3-dose vaccination with investigational formulations compared
with the licensed vaccine was not demonstrated due to anti-pertactin failing to meet the non-inferiority
criterion. Post-primary vaccination, most infants had seroprotective levels of anti-diphtheria (100% of
infants), anti-tetanus antigens (100%), against hepatitis B ( 97.5% across groups), polyribosyl-ribitol-
phosphate ( 88.0%) and poliovirus types 1–3 ( 90.5%). Seropositivity rates for each pertussis antigen
were 100% in all groups.
Higher incidence of fever (> 38C) was reported in infants receiving the investigational formulations
(Primary study: 75.0% [A] and 72.1% [B] vs 58.8% [control]; Booster study, before amendment: 49.4% and
46.6% vs 37.4%, respectively).
The development of the investigational formulations was not further pursued.
KEYWORDS
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Introduction
Combining multiple antigens into a single vaccine has several
potential advantages including simpliﬁed administration,
higher vaccine coverage, reduction in vaccination costs and
number of visits, and minimized risk of administration errors
and missed doses.1,2
A combined hexavalent diphtheria (D), tetanus (T), acellular
pertussis (Pa), hepatitis B (HBV), inactivated poliomyelitis
(IPV), and Haemophilus inﬂuenzae type b (Hib) vaccine
(DTPa-HBV-IPV/Hib; Infanrix hexa, GSK) was ﬁrst autho-
rized for use in 2000.3 DTPa-HBV-IPV/Hib is indicated for pri-
mary vaccination as a 2- or 3-dose primary vaccination course
in infants, followed by a booster vaccination with an interval of
at least 6 months between the last dose of primary vaccination
and the booster dose.
The currently licensed formulation of DTPa-HBV-IPV/
Hib contains D and T antigens from Novartis Vaccines and
Diagnostics, while the other antigens are manufactured in-
house. In response to an increasing demand for DTPa-
based vaccines and to increase supply ﬂexibility, alternative
formulations of diphtheria and tetanus antigens for use in
DTPa combination vaccines have been developed and tested
in pre-clinical settings and were proposed to progress in
clinical evaluation. The historical manufacturing facilities
could potentially not be able to face the increasing require-
ments for DTPa combination vaccines. Increasing the
manufacturing capability would overcome this rising
demand and help controlling the whole manufacturing pro-
cess. Two DTPa-HBV-IPV/Hib formulations containing
new diphtheria and tetanus antigens (DATAPa-HBV-IPV/
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Hib and DBTBPa-HBV-IPV/Hib, formulations A and B,
respectively), detoxiﬁed and adsorbed on aluminum hydrox-
ide used as an adjuvant following 2 different processes (A
and B), were chosen for clinical development. Additionally,
in both investigational formulations, the Hib antigen was
conjugated to the investigational tetanus toxoid (TT). We
aimed to evaluate the immunogenicity and safety of the 2
new formulations administered as a primary 3-dose vacci-
nation to infants at 2, 3 and 4 months of age (Primary vac-
cination study) and as a booster dose at 12–15 months of
age (Booster study). All infants were co-administered with a
13-valent pneumococcal conjugate vaccine (PCV13; Preve-
nar 13TM, Pﬁzer Inc.). The licensed formulation of DTPa-
HBV-IPV/Hib vaccine was used as a benchmark to investi-
gate non-inferiority of the immune response to all vaccine
antigens.
Results
Study participants
In the Primary study, a total of 721 infants, 456 infants from
Finland and 265 infants from Dominican Republic, were
enrolled and included in the total vaccinated cohort (TVC)
(240 received formulation A [group A], 242 received formula-
tion B [group B] and 239 received the licensed vaccine [control
group]); of those, 651 (215 in group A, 217 in group B and 219
in the control group) were included in the according-to-proto-
col (ATP) cohort for immunogenicity (ATP-I) (Fig. 1). Screen
failures were not recorded for the primary study.
In total, 657 infants (409 from Finland and 248 from
Dominican Republic) were enrolled in the Booster study.
The remaining 64 screened participants were not enrolled
in the study due to withdrawal of consent (31), non-
Primary TVC 
N=240 
Booster TVC  
pre*: N=85; post*: N=131 
Enrolled (N=721) 
Group B Group A 
 
Control 
 
2 Withdrawn: Consent withdrawal (1); Death (1) 
Completed N=238 
 
 
25 Excluded: Administration of vaccine(s) 
forbidden in the protocol (3); Study vaccine 
dose not administered according to protocol 
(1); Non-compliance with vaccination schedule 
(11); Non-compliance with blood sampling 
schedule (2); Essential serological data 
missing (8) 
 
ATP cohort for immunogenicity  
N=215 
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N=242 
Primary TVC 
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3 Withdrawn: Consent withdrawal (3) 
 Completed N=239 
1 Withdrawn: Consent withdrawal (1) 
 Completed N=238 
 
25 Excluded: Administration of vaccine(s) 
forbidden in the protocol (1); Administration of 
any medication forbidden by the protocol (1); 
Non-compliance with vaccination schedule (9); 
Non-compliance with blood sampling schedule 
(2); Essential serological data missing (12) 
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Booster TVC  
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Booster TVC  
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(1); Protocol violation (2); Non-compliance with 
blood sampling schedule (1) 
8 Excluded post: Protocol violation (5); Non-
compliance with blood sampling schedule (2); 
Essential serological data missing (1) 
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6 Excluded pre: Administration of vaccine(s) 
forbidden in the protocol (1); Protocol violation 
(2); Non-compliance with blood sampling 
schedule (1); Essential serological data 
missing (2) 
8 Excluded post: Protocol violation (4); Non-
compliance with blood sampling schedule (2); 
Essential serological data missing (2) 
 
Booster ATP immunogenicity 
cohort pre*: N=82; post*: N=122 
9 Excluded pre: Administration of vaccine(s) 
forbidden in the protocol (2); Protocol violation 
(3); Non-compliance with blood sampling 
schedule (1); Essential serological data 
missing (3) 
6 Excluded post: Administration of vaccine(s) 
forbidden in the protocol (1); Study vaccine 
dose not administered according to protocol 
(1); Protocol violation (4);  
Booster ATP immunogenicity 
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Figure 1. Flow of participants in the Primary and Booster vaccination studies. N, number of participants, TVC, total vaccinated cohort; ATP, according to protocol; group A/
group B, infants who received the new formulations A or B of DTPa-HBV-IPV/Hib C PCV13 as a primary vaccination at 2, 3, 4 months of age and a booster dose with the
same vaccine at 12–15 months of age (after protocol amendment, both groups received the licensed DTPa-HBV-IPV/Hib and PCV13 as booster); Control, infants who
received the licensed DTPa-HBV-IPV/Hib C PCV13 as a primary vaccination at 2, 3, 4 months of age and a booster dose at 12–15 months of age; pre, before protocol
amendment; post, after protocol amendment.
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eligibility (14), lost to follow up (8), moving from the study
area (7) or non-willingness for blood sampling (1). One
infant had died (serious adverse event [SAE] described in
Safety – Primary study section) and 2 did not participate
because of an adverse event (AE; acute disease at enrolment
and foot erythema). Initially, 85, 88 and 99 infants were
enrolled in groups A, B and control, respectively, to receive
a booster of the formulation as in the primary study; of
these, 81 (group A), 82 (group B) and 90 (control group)
were included in the ATP-I. Following a high incidence of
fever observed in infants who received the investigational
formulations in the Primary study (see Safety section of the
Results), the study protocol was amended and all infants
(N D 385) who were still to receive the booster dose,
received the licensed formulation as booster. After the pro-
tocol amendment, 131, 130 and 124 infants were included
in groups A, B and control, respectively; of these, 123
(group A), 122 (group B) and 118 (control group) were
included in ATP-I (Table 1).
Immunogenicity
Primary study
The non-inferiority of the immunogenicity of the investiga-
tional DTPa-HBV-IPV/Hib formulations compared with the
licensed vaccine was assessed in terms of seroprotection rates
to diphtheria and tetanus antigens, hepatitis B surface antigens
(HBsAg), and polyribosyl-ribitol-phosphate antigens (PRP, a
polysaccharide component of Haemophilus inﬂuenzae bacte-
rium capsule associated with virulence), and in terms of anti-
body geometric mean concentrations (GMCs) for pertussis
antigens one month after the third vaccine dose. The non-infe-
riority of the investigational DATAPa-HBV-IPV/Hib and
DBTBPa-HBV-IPV/Hib formulations to the licensed vaccine
was not demonstrated as the upper limits (ULs) of the 97.5%
conﬁdence intervals (CIs) of anti-pertactin (PRN) GMC ratio
(control group/investigational formulation) exceeded the pre-
deﬁned limit of 1.5 for both formulations (A: 1.54 and B: 1.84);
of note, the non-inferiority criteria were met for all other anti-
gens (Table 2).
One month post-dose 3, seroprotective/seropositive concen-
trations of antibodies against diphtheria, tetanus and all pertus-
sis antigens were observed in all infants in the 3 groups, and at
least 97.5% of infants in all groups had seroprotective levels of
anti-HBs antibodies, at least 88.0% of infants had anti-PRP
antibody concentrations  0.15 mg/mL, and at least 97.4%,
90.5% and 97.9% of infants had seroprotective titers of antibod-
ies against poliovirus types 1, 2 and 3 across the 3 groups,
respectively (Table 3). Seropositivity rates for each pertussis
antigen were 100% in all groups.
Vaccine response to PT, FHA and PRN was mounted in at
least 97.1%, 96.9% and 91.0% of infants, respectively (Table 4).
Booster study
The percentage of infants with anti-D, anti-T, anti-HBs,
anti-PRP and anti-poliovirus types 1–3 antibody concentra-
tions above the seroprotective cut-offs one month after
booster vaccination was at least 97.3% before the protocol
amendment, and at least 98.3% after the amendment. With
respect to pertussis, higher GMCs were observed when the
licensed vaccine was administered in the primary phase
(Table 3).
Table 1. Summary of demographic characteristics (total vaccinated cohorts).
TVC
Group A (N D 240) Group B (N D 242) Control group (N D 239)
Primary study
Age at dose 1 (we)
Mean 9.7 9.8 9.7
Range (min–max) 8–12 8–12 8–12
Female/male, % 49.6/50.4 57.0/43.0 41.4/58.6
Ancestry, n (%)
White Caucasian 144 (60.0) 148 (61.2) 140 (58.6)
Other 96 (40.0) 94 (38.8) 99 (41.4)
Booster study (Before protocol amendment) Group A (N D 85) Group B (N D 88) Control group (N D 99)
Age at booster dose (mo)
Mean 12.9 13.0 13.0
Range (min–max) 12–15 12–15 12–15
Female/male, % 55.3/44.7 55.7/44.3 38.4/61.6
Ancestry, n (%)
White Caucasian 79 (92.9) 83 (94.3) 91 (91.9)
Other 6 (7.1) 5 (5.7) 8 (8.1)
Booster study (After protocol amendment) Group A (N D 131) Group B (N D 130) Control group (N D 124)
Age at booster dose (mo)
Mean 14.1 13.9 14.0
Range (min-–max) 12–16 12–15 12–15
Female/male, % 46.6/53.4 58.5/41.5 42.7/57.3
Ancestry, n (%)
White Caucasian 49 (37.4) 46 (35.4) 39 (31.5)
Other 82 (62.6) 84 (64.6) 85 (68.5)
N, number of participants; n (%), number (percentage) of participants in a given category; TVC, total vaccinated cohort; we, weeks; mo, months; min, minimum; max, max-
imum. In the Primary and Booster studies (before protocol amendment) groups A and B received the investigational formulations A and B of DTPa-HBV-IPV/Hib C PCV13
at 2, 3 and 4 months of age and as a booster dose at 12–15 months of age; the control group received the licensed DTPa-HBV-IPV/Hib C PCV13 vaccines at 12–15 months
of age. After protocol amendment of the Booster study, all 3 groups received the licensed DTPa-HBV-IPV/Hib C PCV13 vaccines.
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Safety
Primary study
Injection site pain was the most frequently reported soli-
cited local symptom in the 3 groups, reported in 79.2%,
70.4% and 65.1% of infants in groups A, B and control,
respectively; the most common grade 3 solicited local symp-
tom was swelling, reported in 15.4% of infants in group A,
15.0% of infants in group B, and 16.4% of infants in the
control group (Fig. 2A).
Irritability was the most common solicited general symp-
tom in all 3 groups (group A: 82.1%, group B: 85.4%, con-
trol: 80.3%), and was also the most common grade 3
symptom (group A: 14.2%, group B: 17.1%, control: 10.5%)
(Fig. 2B). The incidence of fever reported in infants who
received the investigational formulations appeared higher
compared with control (group A: 75.0%, group B: 72.1%,
control: 58.8%). The incidence of fever was in majority con-
sidered by the investigators to be related to vaccination and
causally related fever incidence was 74.6% in group A,
70.0% in group B and 58.0% in the control group. Grade 3
fever (> 39.0C axillary temperature) was reported for 1.7%
of infants in group A and the control group, and for 2.1%
of infants in group B (Fig. 2B).
During the 31-day post-vaccination period, at least one
unsolicited adverse event was reported for 63.8%, 68.2%, and
66.5% of infants in groups A, B, and control, respectively; grade
3 unsolicited AEs were reported for 7.1%, 8.7% and 6.7% of
infants and unsolicited AEs with a causal relationship to vacci-
nation, for 21.7%, 21.1% and 23.0% of infants in these groups,
respectively.
Twenty-one SAEs were reported for 18 infants (9, 5, and 4
infants in groups A, B and control, respectively). During the
entire study period, one fatal SAE was reported in the Domini-
can Republic in group A 17 d post-dose 1, the reason being
asphyxia and interstitial lung disease. None of the SAEs were
considered by the investigator to be potentially related to
vaccination.
Booster study
Before protocol amendment
The most common solicited local symptom was injection site
pain, reported for 65.9%, 76.1% and 63.6% of infants in groups
A, B, and control, respectively; the most common grade 3 soli-
cited local symptom was swelling, reported in 20.0% of infants
in group A, 11.4% of infants in group B, and 19.2% of infants
in the control group (Fig. 2A).
The incidence of solicited general symptoms ranged from
49.4%–81.2% in group A, from 46.6%–83.0% in group B,
and from 37.4%–74.7% in the control group. Irritability was
the most common solicited general symptom in all 3 groups
(group A: 81.2%, group B: 83.0%, control: 74.7%), and was
also the most common grade 3 symptom (group A: 5.9%,
group B: 4.5%, control: 2.0%) (Fig. 2B). The incidence of
fever appeared higher in groups A (49.4%) and B (46.6%)
compared to control (37.4%); grade 3 fever (> 39.0C axil-
lary temperature) was not reported (Fig. 2B). The incidence
of fever was in majority considered by the investigators to
be related to vaccination and causally related incidence was
49.4% in group A, 45.5% in group B and 36.4% in the con-
trol group.
The incidence of unsolicited AEs reported up to day 31 fol-
lowing vaccination was similar in infants who received the
investigational formulations or the licensed vaccine as booster
(group A: 49.4%, group B: 44.3%, control: 50.5%). No SAEs
were reported before protocol amendment.
After protocol amendment
The most common solicited local symptom in all groups was
injection site pain (58.0% in group A, 50.8% in group B and
51.6% in control group). The most common grade 3 solicited
local symptoms were redness (group A: 6.1%, group B: 6.2%,
control: 6.5%) and swelling (group A: 6.1%, group B: 7.7%, con-
trol: 4.8%).
The most common general symptom in all groups was irri-
tability reported in 50.4%, 44.6% and 50.0% of infants from
Table 2. Group differences in seroprotection/seropositivity rates and adjusted GMC ratio one month post-dose 3 in the Primary vaccination study (ATP cohort for
immunogenicity).
Control Group A
Difference in percentage
(control group minus group A) Group B
Difference in percentage
(control group minus group B)
Antibody n (%) n (%) % (97.5% CI) n (%) % (97.5% CI)
Anti-D (0.1 IU/mL) 219 (100) 214 (100) 0.00 (¡2.25–2.30) 217 (100) 0.00 (¡2.25–2.27)
Anti-T (0.1 IU/mL) 219 (100) 214 (100) 0.00 (¡2.25–2.30) 217 (100) 0.00 (¡2.25–2.27)
Anti- HBs 10 mIU/mL, in-house ELISA 205 (98.1) 197 (97.5) 0.56 (¡3.27–4.63) 203 (99.0) ¡0.94 (¡4.57–2.36)
10 mIU/mL, CLIA adjusted 203 (97.1) 197 (97.5) ¡0.40 (¡4.62–3.80) 201 (98.0) ¡0.92 (¡5.07–3.02)
Anti-PRP (0.15 mg/mL) 193 (88.5) 197 (92.1) ¡3.52 (¡10.19–3.00) 190 (88.0) 0.57 (¡6.53–7.70)
Adjusted GMC
Adjusted GMC ratio
(control group/group A) Adjusted GMC
Adjusted GMC ratio
(control group/group B)
Pertussis antigens Control Group A Value (97.5% CI) Group B Value (97.5% C)
Anti-PT (EU/mL) 73.9 58.5 1.26 (1.11–1.44) 59.0 1.25 (1.10–1.43)
Anti-FHA (EU/mL) 207.6 193.0 1.08 (0.94–1.23) 166.6 1.25 (1.09–1.42)
Anti-PRN (EU/mL) 105.6 79.5 1.33 (1.14–1.54) 66.7 1.58 (1.37–1.84)
ATP, according-to-protocol; n (%), number (percentage) of participants with antibody concentration above the speciﬁed cut-off; CI, conﬁdence interval; D, diphtheria; T,
tetanus; PRP, polyribosyl-ribitol phosphate; HBs, hepatitis B; PT, pertussis toxoid; FHA, ﬁlamentous hemagglutinin; PRN, pertactin; CLIA, ChemiLuminescence ImmunoAs-
say; ELISA, enzyme-linked immunosorbent assay; EU/ml, ELISA units per milliliter; IU/ml, international units per milliliter. Adjusted GMC ratio, geometric mean antibody
concentration adjusted for baseline concentration. In the Primary study, groups A and B received the investigational formulations A and B of DTPa-HBV-IPV/Hib C PCV13
at 2, 3 and 4 months of age; control group received the licensed DTPa-HBV-IPV/HibCPCV13 vaccine at 2, 3 and 4 months of age.
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group A, group B and control, respectively, and was also the
most common grade 3 general symptom (group A: 4.6%, group
B: 1.5%, control: 1.6%).
The incidence of fever was always considered by the
investigators to be related to vaccination and appeared simi-
lar in all groups (group A: 44.3%, group B: 38.5%, control:
41.9%, respectively); grade 3 fever was not reported
(Fig. 2B).
Three SAEs were reported after the amendment, 2 cases of
pneumonia and a case of dehydration (all in group B); none
were considered by the investigator to be related to vaccination
and all recovered before the study end.
Table 4. Vaccine response rate to anti-PT, anti-FHA and anti-PRN antibodies one month post-primary vaccination (ATP cohort for immunogenicity).
% Vaccine response (95% CI)
Antibody Group A (N D 181) Group B (N D 194) Control (N D 198)
Anti-PT 98.0 (94.9–99.4) 97.1 (93.9–98.9) 99.0 (96.6–99.9)
Anti-FHA 96.9 (93.5–98.9) 97.6 (94.5–99.2) 98.1 (95.1–99.5)
Anti-PRN 91.0 (86.1–94.6) 93.3 (89.0–96.3) 94.3 (90.2–97.0)
ATP, according-to-protocol; %, percentage of infants with vaccine response; CI, conﬁdence interval; PT, pertussis toxoid; FHA, ﬁlamentous hemagglutinin; PRN, pertactin;
N, minimum number of infants with available results.
Groups A and B received the investigational formulations A and B of DTPa-HBV-IPV/Hib C PCV13 at 2, 3 and 4 months of age.
Control group received the licensed DTPa-HBV-IPV/Hib C PCV13 vaccines at 2, 3 and 4 months of age.
Vaccine response was deﬁned as a post-dose 3 antibody concentration  5 ELISA units/mL (EU/mL) for initially seronegative infants, or an antibody concentration  1-
fold the pre-vaccination antibody concentration for initially seropositive infants. Infants with antibody concentration < 5 EU/mL before vaccination were considered
seronegative; infants with antibody concentration  5 EU/mL before vaccination were considered seropositive.
Figure 2. Incidence of solicited local (A) and general symptoms (B) in Primary (day 0–7) and Booster study (day 0–4) (total vaccinated cohorts). Group A/Group B, infants
who received the new formulations A or B of DTPa-HBV-IPV/Hib C PCV13 as a primary vaccination at 2, 3, 4 months of age and a booster dose with the same vaccine at
12–15 months of age (after protocol amendment, both groups received the licensed DTPa-HBV-IPV/Hib C PCV13 as booster); Control, infants who received the licensed
DTPa-HBV-IPV/Hib C PCV13 as a primary vaccination at 2, 3, 4 months of age and a booster dose at 12–15 months of age; Pri, primary vaccination; Pre, booster vaccina-
tion before protocol amendment; Post, booster vaccination after protocol amendment. The error bars indicate 95% conﬁdence intervals.
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Discussion
The immunogenicity of the investigational DTPa-HBV-IPV/
Hib formulations administered to infants as a 3-dose primary
vaccination was inferior to the licensed DTPa-HBV-IPV/Hib
vaccine and the reactogenicity was higher.
In the Primary vaccination study reported in this manuscript,
the incidence of fever following 3 doses of the investigational
DTPa-HBV-IPV/Hib formulations was much higher (group A:
75.0%, group B: 72.1%), and was likely either due to the new for-
mulations of the diphtheria and tetanus antigens or to the PRP that
was conjugated to the investigational tetanus antigen. Nevertheless,
the incidence of grade 3 fever reported for the investigational vac-
cine formulation post-primary vaccination was low (1.7%–2.1%
across the groups), similar to previously reported for the investiga-
tional DTaP5-IPV-Hib-HepB formulation (2%).4
Altogether, the results of the Primary and Booster vaccina-
tion studies presented in this manuscript indicate that the
DTPa-HBV-IPV/Hib vaccine formulations containing investi-
gational diphtheria and tetanus antigens are associated with a
lower immunogenicity and a higher reactogenicity compared
to the licensed DTPa-HBV-IPV/Hib vaccine. The incidence of
SAEs was low, consistent with the results of previous studies
with the DTPa-HBV-IPV/Hib vaccine.5,6 This ﬁnding empha-
sizes the need to carry out head-to-head comparisons for any
new compositions of hexavalent vaccine. This experience sug-
gests that the formulation of a hexavalent vaccine is sensitive to
changes in the vaccine components and new experimental
combinations may be less immunogenic than the licensed
Infanrix hexa.
In the light of waning immunity following vaccination with
acellular pertussis vaccines, the need for a new generation of pertus-
sis vaccines is recognized. Alternative formulations might be
improved with the addition of more or improved antigens to the
multicomponent vaccines, removal of antigens or adjuvant
improvement, or use of DNAor attenuated, live bacterial vaccines.7
The studies had the following strengths: (1) enrolment from
different settings (Finland and Dominican Republic) allowed
assessing whether the observed effects were country speciﬁc;
(2) the short vaccination schedule provided a worst case sce-
nario for assessing seroprotection by the different vaccine for-
mulations; (3) the drop-out rate was reasonably low for this
type of study as approximately 85% of the infants completed
both primary and booster studies. Another advantage of the
study design was the availability of blood samples pre-vaccina-
tion, allowing anti-pertussis geometric mean titer (GMT) group
comparisons while accounting for the pre-vaccination
immunogenicity.
Potential limitations of the studies include the fact that
inferential analysis linked to the primary objective in the
Booster study could not be performed due to failure of the pri-
mary non-inferiority objective in the Primary vaccination study
and due to the protocol amendment.
As the investigational formulations of the DTPa-HBV-IPV/
Hib failed to demonstrate non-inferiority of the vaccine immu-
nogenicity to the licensed formulation, and because of a higher
incidence of fever associated with the investigational formula-
tions compared to the licensed vaccine, the development of the
investigational formulations was not further pursued.
Patients and Methods
Study design
The Primary vaccination study was a phase I/II double-blind,
randomized, multicenter study conducted in 2 centers in the
Dominican Republic and 14 centers in Finland between
December 2010 and January 2012. Healthy infants were ran-
domized (1:1:1) to receive 3 doses of 2 investigational DTPa-
HBV-IPV/Hib formulations (A or B; group A and B, respec-
tively) or the licensed DTPa-HBV-IPV/Hib formulation (con-
trol group) at 2, 3, 4 months of age; in addition, all infants
received concomitant injections of PCV13.
Infants who received 3 doses of either formulation of
DTPa-HBV-IPV/Hib vaccine (A, B or control [licensed vac-
cine]) in the Primary study were invited to participate in a
follow-up, phase II, randomized, double-blind Booster vac-
cination study (October 2011–November 2012) to evaluate
the response to the booster vaccination with DTPa-HBV-
IPV/Hib received between 12 and 15 months of age. Infants
participating in the Booster study retained the group alloca-
tion to which they were randomized in the Primary study.
In addition, all infants received a concomitant booster dose
of PCV13.
Initially, infants received a booster dose with the same vac-
cine formulations as in the Primary study; following a protocol
amendment (see Results section), infants in all 3 groups
received the licensed DTPa-HBV-IPV/Hib formulation as
booster dose. The double-blinding regarding the vaccine
received during the Primary study was maintained until the
end of the Booster study.
Written informed consent was obtained for each infant from
the parent or the legally acceptable representative (LAR). The
study was conducted according to the Declaration of Helsinki,
Good Clinical Practice, International Conference on Harmoni-
sation (ICH) Harmonised Tripartite Guideline for clinical
investigation of medicinal products in the pediatric population
(ICH E11), and the Finnish and Dominican laws and regula-
tions. The study protocol, the amendments, the informed con-
sent, and all documents requiring pre-approval were reviewed
and approved by an Institutional Review Board or an Indepen-
dent Ethics Committee.
The studies are registered at www.clinicaltrials.gov
(NCT01248884 and NCT01453998). A summary of each study
protocol is available at http://www.gsk-clinicalstudyregister.
com (GSK study ID: 113948 and 114843).
Study objectives
Primary vaccination study
The primary objective of the study was to demonstrate non-
inferiority of at least one of the 2 investigational DTPa-HBV-
IPV/Hib formulations compared with the licensed formulation
in terms of seroprotection rates to diphtheria, tetanus, HBsAg
and PRP antigens, and in terms of antibody GMCs for pertussis
antigens one month after the third dose.
The secondary objectives included the assessment of the
immune response to the study vaccines in terms of: seroprotec-
tion/seropositivity and antibody concentrations or titers, one
month after the third dose; immunological status toward
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diphtheria, tetanus, pertussis and polio antigens; seroprotec-
tion/seropositivity and antibody concentrations before the pri-
mary vaccination; and vaccine response to pertussis antigens
one month after the third dose; the assessment of the safety
and reactogenicity of the study vaccines.
Booster study
The primary objective was to demonstrate non-inferiority of at
least one of the 2 investigational DTPa-HBV-IPV/Hib formula-
tions compared with the licensed formulation in terms of sero-
protection rates to diphtheria, tetanus, HBsAg, poliovirus types
1, 2 and 3 and PRP antigens, and in terms of GMCs for pertus-
sis antigens one month after the booster dose.
Before protocol amendment, participants received a booster
dose of the same vaccine they received as primary vaccination
course. Following the protocol amendment, all the participants
yet to receive the booster dose, received the licensed DTPa-
HBV-IPV/Hib formulation. Accordingly, as only less than half
of the participants could contribute to the initial study objec-
tives leading to a study power lower than 50%, the inferential
non-inferiority analysis was not performed, but separate
descriptive analyses of the cohorts enrolled before and after the
amendment were performed (see Statistical analysis section).
Secondary objectives included the assessment of the persis-
tence of antibodies to all vaccine antigens at pre-booster; immune
responses to the study vaccines in terms of seroprotection/sero-
positivity status and antibody concentrations or titers for all vac-
cine antigens, and in terms of booster response for pertussis
antigens one month after booster vaccination; as well as the
assessment of the safety and reactogenicity of the booster dose.
Study participants
Participants eligible for the Primary study were healthy infants
(as established by medical history and clinical examination
before entering into the study) 60–90 d of age, born after a ges-
tation period of 37–42 weeks, for whom written informed con-
sent was obtained from the infant’s parent(s) or LAR(s).
Participants eligible for the Booster study were healthy tod-
dlers aged 12–15 months at the time of the booster vaccination
who participated in the Primary study where they received 3
doses of the investigational or licensed formulation of DTPa-
HBV-IPV/Hib vaccine, and for whom written informed con-
sent was obtained.
Infants were excluded if they received any investigational or
non-registered drug or vaccine within 30 d preceding the ﬁrst/
booster dose of the study vaccine or had a planned administration
of such products during the studies. Infants who had fever (tem-
perature  37.5C on axillary, oral or tympanic setting, or 
38.0C on rectal setting) at the time of enrolment or who had
intercurrent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis
B, Hib and/or pneumococcal vaccination or disease were
excluded from both studies. HBV vaccination at birth and oral
rotavirus vaccination were allowed at any time during the study.
Study vaccines
Each 0.5mL dose of DTPa-HBV-IPV/Hib contained 30 interna-
tional units (IU) diphtheria toxoid,  40 IU TT, 25 mg PT, 25 mg
FHA, 8 mg PRN, 10 mg recombinant HBs, 40 D-Antigen Units
(DAgU) poliovirus type 1, 8 DAgU poliovirus type 2, 32 DAgU
poliovirus type 3, 10 mg PRP conjugated to 20–40 mg TT, and
0.82 mg aluminum as salts. The 2 investigational formulations (A
and B) of DTPa-HBV-IPV/Hib contained new diphtheria and teta-
nus antigens that differed in the process by which the detoxiﬁed
antigens were adsorbed onto aluminum hydroxide, used as an
adjuvant. The PRP antigen was conjugated to new TT while the
other antigens were identical.
The composition of PCV13, a CRM197 conjugated pneumo-
coccal vaccine, has been described previously.8
Immunogenicity assessment
For each study, 2 blood samples for the analysis of antibody
response were collected from all infants, before the ﬁrst vaccine
dose or booster and one month post-dose 3 or post-booster
vaccination.
Anti-diphtheria and anti-tetanus antibodies were evaluated
by an enzyme-linked immunosorbent assay (ELISA) developed
in-house; seroprotection was deﬁned as antibody concentra-
tions  0.1 IU/mL. Anti-pertussis (anti-PT, anti-FHA and
anti-PRN) antibodies were measured by ELISA (developed in-
house) and seropositivity was deﬁned as antibody concentra-
tions above the cut-off of 5 EU/ml (ELISA units per millili-
ter).9,10 Antibodies against poliovirus types 1, 2 and 3 were
determined by a virus micro-neutralization test (developed in-
house),11 with antibody titers  8 ED50 (median effective dose)
considered protective. Anti-PRP antibodies were measured by
ELISA (developed in-house), with antibody concentrations 
0.15 mg/mL considered as protective.12,13
Regarding anti-HBs, investigations on the quality of some
serology assays revealed that the anti-HBs in-house developed
ELISA overestimated concentrations between 10–100 mIU/mL,
while values above 100 mIU/mL were conﬁrmed valid. There-
fore, all available samples at one month after the primary vacci-
nation for which the anti-HBs antibody concentration was
between 10–100 mIU/mL by the in-house ELISA, were retested
by the commercial ChemiLuminescence ImmunoAssay (CLIA;
CentaurTM, Siemens Healthineers) with a cut-off deﬁning sero-
positivity of 6.2 mIU/mL. Anti-HBs seroprotection was rede-
ﬁned as in-house ELISA14,15 concentration above 100 mIU/mL
or CLIA concentration above 10 mIU/mL. CLIA was also used
as an immunogenicity assay for the Booster study. GSK Biologi-
cals’ clinical laboratories tested the samples.
Safety assessment
Enrollment in the Primary study adopted a staggered approach
and an interim safety evaluation was done to cautiously test the
new formulation. During a ﬁrst randomization wave, 96 infants
were enrolled. A review of the safety data of those infants trig-
gered the second enrollment wave at all study sites. Recruit-
ment completed when at least 720 infants had been enrolled.
Solicited local (pain, redness, swelling) and general (drowsi-
ness, irritability/fussiness, loss of appetite, fever [temperature 
37.5C on axillary]) symptoms were recorded up to 8 d after
each formulation dose in the Primary study, and up to 4 d
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post-vaccination in the Booster study. Unsolicited AEs were
recorded up to 31 d post-vaccination.
Grade 3 symptoms were deﬁned as AEs preventing normal
activity, pain upon limb movement or a spontaneously painful
limb, irritability/fussiness resulting in crying that cannot be
comforted, drowsiness that prevents normal activity, loss of
appetite resulting in not eating at all, and grade 3 fever, as tem-
perature > 39C on axillary setting. All solicited local (injection
site) reactions were considered causally related to vaccination.
Causality of all other AEs was assessed by the investigator.
SAEs were recorded throughout the studies.
Statistical analyses
For the Primary study, the sample size was calculated to meet
the primary objectives with an overall power of at least 80%
and assuming approximately 10% of non-evaluable results. A
maximum of 720 (240 per group) infants were expected to be
enrolled in the Primary study and therefore, potentially eligible
for the Booster study, to achieve the primary objective of non-
inferiority for at least one of the 2 formulations.
Descriptive statistics was used to summarize demographic
characteristics. In the Primary study, the primary analyses for
immunogenicity were based on the ATP-I. A second immuno-
genicity analysis was performed on the TVC to complement
the ATP analysis. The 2 investigational formulations were
assessed independently. For each new formulation, non-inferi-
ority for immunogenicity concerning the primary endpoints
was assessed sequentially according to the ranking: diphtheria,
tetanus, HBs, PT, FHA, PRN and PRP. For each new formula-
tion, a conclusion on one objective was only possible if the pre-
ceding objective with a lower rank had been demonstrated
before.
The non-inferiority in terms of immune response to diph-
theria, tetanus, HBs and PRP antigens was demonstrated if the
ULs of the standardized asymptotic 97.5% CIs of the group dif-
ference (control group minus each investigational group [A or
B]) in terms of percentage of seroprotected participants for
each antigen were  10%. The non-inferiority in terms of
immune response to pertussis antigens was demonstrated if the
ULs of the 97.5% CI on the GMC ratio (control divided by
each investigational group) was  1.5.
In both studies, descriptive analysis was done for each group, at
each timepoint and for each antigen for which a serological result
was available (seropositivity/seroprotection/vaccine response rates
with exact 95% CIs, and GMCs or GMTs with 95% CIs).
The safety analyses were performed on the TVCs.
Trademark
Infanrix hexa is a trademark of the GSK group of companies.
Prevenar 13 is a trademark of Pﬁzer Inc.
On 2 March 2015 Novartis non-inﬂuenza Vaccines Business
was acquired by the GSK group of companies.
Trial registration
NCT01248884 and NCT01453998 (www.clinicaltrials.gov).
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AE adverse events
ATP according-to-protocol
ATP-I according-to-protocol cohort for
immunogenicity
CI conﬁdence interval
CLIA ChemiLuminescence ImmunoAssay
DAgU D-Antigen Units
DATAPa-HBV-IPV/Hib formulation A of DTPa-HBV-IPV/
Hib
DBTBPa-HBV-IPV/Hib formulation B of DTPa-HBV-IPV/
Hib
DTPa-HBV-IPV/Hib combined hexavalent vaccine against
diphtheria, tetanus, pertussis, hepati-
tis B, poliomyelitis and Hib
ED50 median effective dose
ELISA enzyme-linked immunosorbent
assay
FHA ﬁlamentous hemagglutinin
GMC geometric mean concentration
GMT geometric mean titer
HB hepatitis B
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
Hib Haemophilus inﬂuenzae type b
IU international units
LAR legally acceptable representative
Pa acellular pertussis
PCV13 13-valent pneumococcal conjugated
vaccine
PRN pertactin
PRP polyribosyl-ribitol-phosphate
PT pertussis toxoid
SAEs serious adverse events
T tetanus
TT tetanus toxoid
TVC total vaccinated cohort
UL upper limit
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